The death of cost‐minimization analysis?
- 9 March 2001
- journal article
- research article
- Published by Wiley in Health Economics
- Vol. 10 (2), 179-184
- https://doi.org/10.1002/hec.584
Abstract
Four different types of evaluation methods, cost‐benefit analysis (CBA), cost‐utility analysis (CUA), cost‐effectiveness analysis (CEA) and cost‐minimization analysis (CMA), are usually distinguished. In this note, we pronounce the (near) death of CMA by showing the rare circumstances under which CMA is an appropriate method of analysis. We argue that it is inappropriate for separate and sequential hypothesis tests on differences in effects and costs to determine whether incremental cost‐effectiveness (or cost‐utility) should be estimated. We further argue that the analytic focus should be on the estimation of the joint density of cost and effect differences, the quantification of uncertainty surrounding the incremental cost‐effectiveness ratio and the presentation of such data as cost‐effectiveness acceptability curves. Two examples from recently published CEA are employed to illustrate the issues. The first shows a situation where analysts might be tempted (inappropriately) to employ CMA rather than CEA. The second illustrates one of the rare circumstances in which CMA may be justified as a legitimate form of analysis. Copyright © 2001 John Wiley & Sons, Ltd.Keywords
This publication has 19 references indexed in Scilit:
- Meta-analysis of the implantable cardioverter defibrillator secondary prevention trialsEuropean Heart Journal, 2000
- Carrier Screening for Cystic FibrosisMedical Decision Making, 1998
- Low-Molecular-Weight HeparinsNew England Journal of Medicine, 1997
- Guidelines for authors and peer reviewers of economic submissions to the BMJBMJ, 1996
- Statistics notes: Absence of evidence is not evidence of absenceBMJ, 1995
- Costs, effects and C/E‐ratios alongside a clinical trialHealth Economics, 1994
- Cost-utility analysis.BMJ, 1993
- Cost-effectiveness analysis.BMJ, 1993
- Costs and cost-minimisation analysis.BMJ, 1993
- The Importance of Beta, the Type II Error and Sample Size in the Design and Interpretation of the Randomized Control TrialNew England Journal of Medicine, 1978